Dominari (DOMH) to Release Quarterly Earnings on Monday

Dominari (NASDAQ:DOMH) is expected to release its results before the market opens on Monday, March 30th. Analysts expect Dominari to post earnings of ($0.17) per share and revenue of $56.82 million for the quarter.

Dominari Stock Performance

NASDAQ DOMH opened at $3.10 on Friday. Dominari has a twelve month low of $2.76 and a twelve month high of $8.40. The stock has a market cap of $50.28 million, a PE ratio of 0.56 and a beta of 0.83. The firm has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $4.66.

Institutional Trading of Dominari

Several institutional investors have recently made changes to their positions in the business. Creek Drive Management Group LLC acquired a new stake in shares of Dominari during the 4th quarter valued at about $1,861,000. Vanguard Group Inc. lifted its stake in Dominari by 8.0% during the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after purchasing an additional 25,694 shares during the period. Connective Capital Management LLC lifted its stake in Dominari by 26.2% during the third quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after purchasing an additional 69,545 shares during the period. Two Sigma Investments LP acquired a new stake in Dominari during the third quarter valued at approximately $771,000. Finally, Geode Capital Management LLC boosted its holdings in Dominari by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 88,293 shares of the company’s stock valued at $437,000 after purchasing an additional 7,244 shares in the last quarter. 42.48% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.